Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Spleen Tyrosine Kinase (SYK): Overview
SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.
Structure and Signaling of the SYK Receptor
SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain. These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.
The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.
Expression
SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.
Spleen Tyrosine Kinase (SYK) Inhibitors
While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ?2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Chapters
This segment of the Spleen Tyrosine Kinase (SYK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs
Further product details are provided in the report……..
Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Spleen Tyrosine Kinase (SYK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spleen Tyrosine Kinase (SYK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen Tyrosine Kinase (SYK) Inhibitors drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Spleen Tyrosine Kinase (SYK): Overview
SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.
Structure and Signaling of the SYK Receptor
SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain. These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.
The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.
Expression
SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.
Spleen Tyrosine Kinase (SYK) Inhibitors
While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ?2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Chapters
This segment of the Spleen Tyrosine Kinase (SYK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs
- Cevidoplenib dimesylate: Genosco
- HMPL-523: Hutchison MediPharma
Further product details are provided in the report……..
Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Spleen Tyrosine Kinase (SYK) Inhibitors
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Molecule Type
- Monoclonal antibodies
- Small molecules
- Product Type
Spleen Tyrosine Kinase (SYK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spleen Tyrosine Kinase (SYK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen Tyrosine Kinase (SYK) Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spleen Tyrosine Kinase (SYK) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Spleen Tyrosine Kinase (SYK) Inhibitors.
- August 2020: SKI-O-703 (SYK inhibitor) is currently undergoing two Phase 2 clinical trials in rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura (ITP).
- Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spleen Tyrosine Kinase (SYK) Inhibitors drugs?
- How many Spleen Tyrosine Kinase (SYK) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spleen Tyrosine Kinase (SYK) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spleen Tyrosine Kinase (SYK) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spleen Tyrosine Kinase (SYK) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genosco
- Portola Pharmaceuticals
- GlaxoSmithKline
- FUJIFILM Corporation
- TopiVert
- Takeda Oncology
- Asana BioSciences
- CVXL-0074
- Cevidoplenib
- PRT 2761
- GSK 2646264
- Cevidoplenib
- FF 10102 01
- TOP 1630
- Mivavotinib
Introduction
Executive Summary
Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
SYK Receptor - Overview
Structure and Signaling of the SYK Receptor
Regulation of Synthesis and Release of SYK
SYK Metabolism
SYK Receptor Antagonists
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Spleen Tyrosine Kinase (SYK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
TOP 1630: TopiVert
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Cevidoplenib: Genosco
Product Description
Research and Development
Product Development Activities
PRT 2761: Portola Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I/II)
Comparative Analysis
Gusacitinib: Asana BioSciences
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
Mivavotinib: Takeda Oncology
Product Description
Research and Development
Product Development Activities
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: small molecule therapeutics: Genosco
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
Spleen Tyrosine Kinase (SYK) Inhibitors Key Products
Spleen Tyrosine Kinase (SYK) Inhibitors- Unmet Needs
Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
Spleen Tyrosine Kinase (SYK) Inhibitors- Future Perspectives and Conclusion
Spleen Tyrosine Kinase (SYK) Inhibitors Analyst Views
Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
Appendix
Executive Summary
Spleen Tyrosine Kinase (SYK) Inhibitors: Overview
SYK Receptor - Overview
Structure and Signaling of the SYK Receptor
Regulation of Synthesis and Release of SYK
SYK Metabolism
SYK Receptor Antagonists
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Spleen Tyrosine Kinase (SYK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Spleen Tyrosine Kinase (SYK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Spleen Tyrosine Kinase (SYK) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
Comparative Analysis
TOP 1630: TopiVert
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Cevidoplenib: Genosco
Product Description
Research and Development
Product Development Activities
PRT 2761: Portola Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I/II)
Comparative Analysis
Gusacitinib: Asana BioSciences
Product Description
Research and Development
Product Development Activities
Early Stage Products (Phase I)
Comparative Analysis
Mivavotinib: Takeda Oncology
Product Description
Research and Development
Product Development Activities
Pre-clinical and Discovery Stage Products
Comparative Analysis
Research programme: small molecule therapeutics: Genosco
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
Spleen Tyrosine Kinase (SYK) Inhibitors Key Products
Spleen Tyrosine Kinase (SYK) Inhibitors- Unmet Needs
Spleen Tyrosine Kinase (SYK) Inhibitors- Market Drivers and Barriers
Spleen Tyrosine Kinase (SYK) Inhibitors- Future Perspectives and Conclusion
Spleen Tyrosine Kinase (SYK) Inhibitors Analyst Views
Spleen Tyrosine Kinase (SYK) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Spleen Tyrosine Kinase (SYK) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
